Clinical outcome of biomarker-guided therapies in adult patients with tumors of the nervous system

Abstract Background The clinical utility of molecular profiling and targeted therapies for neuro-oncology patients outside of clinical trials is not established. We aimed at investigating feasibility and clinical utility of molecular profiling and targeted therapy in adult patients with advanced tumors in the nervous system within a prospective observational study. Methods molecular tumor board (MTB)@ZPM (NCT03503149) is a prospective observational precision medicine study for patients with advanced tumors. After inclusion of patients, we performed comprehensive molecular profiling, formulated ranked biomarker-guided therapy recommendations based on consensus by the MTB, and collected prospective clinical outcome data. Results Here, we present initial data of 661 adult patients with tumors of the nervous system enrolled by December 31, 2021. Of these, 408 patients were presented at the MTB. Molecular-instructed therapy recommendations could be made in 380/408 (93.1%) cases and were prioritized by evidence levels. Therapies were initiated in 86/380 (22.6%) cases until data cutoff. We observed a progression-free survival ratio >1.3 in 31.3% of patients. Conclusions Our study supports the clinical utility of biomarker-guided therapies for neuro-oncology patients and indicates clinical benefit in a subset of patients. Our data might inform future clinical trials, translational studies, and even clinical care.

[1]  K. Hoang-Xuan,et al.  European Association of Neuro-Oncology (EANO) Guidelines for Treatment of Primary Central Nervous System lymphoma (PCNSL). , 2022, Neuro-oncology.

[2]  M. Gilbert,et al.  Case report: Oligodendroglioma, IDH-mutant and 1p/19q-codeleted, associated with a germline mutation in PMS2 , 2022, Frontiers in Oncology.

[3]  P. Wen,et al.  Eano-Euracan-Sno Guidelines on Circumscribed Astrocytic GLIOMAS, Glioneuronal and Neuronaltumors. , 2022, Neuro-oncology.

[4]  O. Griffith,et al.  Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). , 2022, Genetics in medicine : official journal of the American College of Medical Genetics.

[5]  P. Brown,et al.  Treatment for Brain Metastases: ASCO-SNO-ASTRO Guideline. , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. J. van den Bent,et al.  Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults: ASCO-SNO Guideline , 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Kimberly J. Johnson,et al.  Brain tumor biomarkers for research, clinics, and registries - The 2021 Brain Tumor Epidemiology Consortium meeting report. , 2021, Clinical Neuropathology.

[8]  David C. Jones,et al.  The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets , 2021, Cancer discovery.

[9]  D. Schadendorf,et al.  EANO-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  G. Reifenberger,et al.  The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.

[11]  M. Weller,et al.  EANO guideline on the diagnosis and management of meningiomas. , 2021, Neuro-oncology.

[12]  C. von Kalle,et al.  Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers. , 2021, Cancer discovery.

[13]  S. Shete,et al.  Partitioned glioma heritability shows subtype-specific enrichment in immune cells. , 2021, Neuro-oncology.

[14]  E. Rogozińska,et al.  Treatment options for progression or recurrence of glioblastoma: a network meta-analysis. , 2021, The Cochrane database of systematic reviews.

[15]  G. Reifenberger,et al.  EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood , 2020, Nature Reviews Clinical Oncology.

[16]  Melanie Boerries,et al.  Variant classification in precision oncology , 2019, International journal of cancer.

[17]  S. Fröhling,et al.  Community-driven development of a modified progression-free survival ratio for precision oncology , 2019, ESMO Open.

[18]  J Jack Lee,et al.  Genomic and transcriptomic profiling expands precision cancer medicine: the WINTHER trial , 2019, Nature Medicine.

[19]  David T. W. Jones,et al.  N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma. , 2018, Neuro-oncology.

[20]  N. Schultz,et al.  A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[21]  David T. W. Jones,et al.  Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study , 2018, Neuro-oncology.

[22]  J. Hainsworth,et al.  Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J Bogaerts,et al.  ESMO-Magnitude of Clinical Benefit Scale version 1.1 , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Marie-Cécile Le Deley,et al.  High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial. , 2017, Cancer discovery.

[25]  Benjamin M. Ellingson,et al.  Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials , 2017, Neurotherapeutics.

[26]  Marilyn M. Li,et al.  Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.

[27]  Razelle Kurzrock,et al.  Association of Biomarker-Based Treatment Strategies With Response Rates and Progression-Free Survival in Refractory Malignant Neoplasms: A Meta-analysis. , 2016, JAMA oncology.

[28]  Jonathan R. Dry,et al.  Defining actionable mutations for oncology therapeutic development , 2016, Nature Reviews Cancer.

[29]  J. Colwell.  NCI-MATCH Trial Draws Strong Interest. , 2016, Cancer discovery.

[30]  Naoya Hashimoto,et al.  Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. , 2015, The Lancet. Oncology.

[31]  Nicolas Servant,et al.  Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial. , 2015, The Lancet. Oncology.

[32]  J Jack Lee,et al.  Impact of Precision Medicine in Diverse Cancers: A Meta-Analysis of Phase II Clinical Trials. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  S. Shete,et al.  Description of selected characteristics of familial glioma patients - results from the Gliogene Consortium. , 2013, European journal of cancer.

[34]  L Junck,et al.  Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. , 2011, The Lancet. Oncology.

[35]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R Miike,et al.  Familial and personal medical history of cancer and nervous system conditions among adults with glioma and controls. , 1997, American journal of epidemiology.